#USA #New York #Pomerantz #RZLT #Rezolute

Overview of the Investigation

Recently, the Pomerantz Law Firm announced its investigation into Rezolute, Inc. (NASDAQ: RZLT) on behalf of its investors. The investigation primarily focuses on whether Rezolute and its executives have conducted securities fraud or engaged in unlawful business tactics. Investors are strongly encouraged to reach out to Pomerantz for further details on how they may be impacted.

The Significance of the Press Release

A current concern for investors arose after Rezolute released critical insights regarding its clinical trials on December 11, 2025. This press release reported discouraging topline results from its Phase 3 clinical trial, known as the sunRIZE study, which evaluated the treatment efficacy of ersodetug for patients suffering from congenital hyperinsulinism. The company disclosed that the study failed to meet its primary endpoint concerning the average weekly hypoglycemia events as determined by self-monitored blood glucose.

Breakdown of the Study Results

Although Rezolute outlined a 45% reduction in hypoglycemia incidents at the maximum dose of ersodetug (10 mg/kg), this statistic was not found to be statistically significant compared to the placebo group, which had a 40% improvement. Furthermore, under the key secondary endpoint measuring average daily hypoglycemia time using continuous glucose monitoring (CGM), participants receiving the treatment experienced about a 25% reduction in hypoglycemia time, also deemed statistically insignificant when contrasted with the placebo group, which saw a minor increase of approximately 5%.

Impact on Stock Prices

In light of these revelations from the study, Rezolute's stock suffered a notable decline, plummeting by $9.44 per share, which equates to a staggering 87.2% drop. This price tumble was alarming for shareholders, with the stock closing at $1.77 per share on December 19, 2025. The dramatic shift in stock performance has prompted the current investigation by Pomerantz.

About Pomerantz Law Firm

The Pomerantz Law Firm, with locations in prominent cities like New York, Chicago, and Los Angeles, is recognized as a leader in corporate, securities, and antitrust class action litigation. Founded by the legendary Abraham L. Pomerantz, noted for his contributions to class action laws, the firm has continued to uphold the values established over 85 years ago, advocating for victims of securities fraud and corporate misconduct. Their long history includes securing substantial damages for members of class action lawsuits.

Call to Action for Affected Investors

Investors who feel affected by these developments or believe they may have been misled by Rezolute's disclosures are urged to contact Pomerantz by reaching out to Danielle Peyton at [email protected] or calling 646-581-9980, ext. 7980, for potential involvement in this investigation. Pomerantz continues its commitment to providing justice for investors affected by corporate deceit and fraudulent practices.

In conclusion, as Rezolute navigates through these troubled waters, all eyes will be on the outcomes of the Pomerantz-led investigation and its ramifications for investors, with many hoping for accountability and transparency moving forward.